文献速递慢性肾脏病肾小球疾病肾血管病与高血压

印度轻中度慢性肾脏病患者的处方实践

Prescription Practices in Patients With Mild to Moderate CKD in India.
PubMed 文献 · Kidney Int Rep · 2021-06-26

基于印度慢性肾脏病(ICKD)前瞻性队列的基线数据,分析3966例轻中度CKD患者的处方模式。多数为CKD 3期,87%合并高血压,但肾素-血管紧张素-醛固酮系统阻滞剂使用率不足一半,他汀、铁剂及促红细胞生成素使用率偏低,提示循证治疗存在显著缺口。

要点

  • 轻中度CKD患者中,肾素-血管紧张素-醛固酮系统阻滞剂总体使用率仅47.9%,蛋白尿性CKD中为58.8%。
  • 合并贫血者仅31.1%使用铁剂、2.8%使用促红细胞生成素;糖尿病患者二甲双胍使用率25.7%。
  • 仅40.4%患者使用他汀,提示循证治疗落实不足,需推广指南与实施策略。

核心结论

  • 印度轻中度CKD患者中循证治疗处方存在明显不足,错失改善预后的机会。
  • 需传播循证指南并建立可持续的实施策略以改善CKD患者整体健康。

研究设计与样本

  • ICKD研究为前瞻性观察性队列,覆盖印度11个中心。
  • 分析入组时全部处方,共3966/4056例(97.8%)有完整处方数据。

主要发现

  • 多数患者为CKD 3期,24.9%为糖尿病肾脏病,87%有高血压,25.5%有中重度蛋白尿。
  • 肾素-血管紧张素-醛固酮系统阻滞剂总体使用率47.9%,蛋白尿性CKD中58.8%。
  • 糖尿病患者二甲双胍使用率25.7%;他汀总体使用率40.4%。
  • 贫血患者中铁剂使用率31.1%,促红细胞生成素使用率2.8%。

临床怎么用

  • 应提高肾素-血管紧张素-醛固酮系统阻滞剂在蛋白尿性CKD中的使用率。
  • 应加强他汀、铁剂及促红细胞生成素的合理处方以改善并发症管理。
  • 需推广循证指南并建立可持续的实施策略。

局限性

  • 仅描述基线处方,未报告随访结局或处方与预后关联。
  • 数据来自印度多中心队列,外推至其他低中等收入国家需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with chronic kidney disease (CKD) require multiple medications. There is no information on prescription patterns or the use of evidence-based therapies for management of CKD from low-middle-income countries. Using baseline data from the Indian CKD (ICKD) cohort, we describe the drug prescription practices in patients with mild to moderate CKD. METHODS: The ICKD study is a prospective, observational cohort study of mild to moderate kidney disease across 11 centers in India. We analyzed all the prescriptions captured at enrollment in the ICKD study. Drugs were categorized into 11 different groups. We provide descriptive data on prescription details and evaluate the appropriateness of medication use. RESULTS: Complete prescription data were available in 3966 out of 4056 (97.8%) subjects enrolled in the ICKD database. Most patients had stage 3 CKD, 24.9% had diabetic kidney disease, 87% had hypertension, and 25.5% had moderate to severe proteinuria. Renin-angiotensin-aldosterone system blockers were prescribed in less than half (47.9%) and in 58.8% of patients with proteinuric CKD. Metformin was prescribed in 25.7% of diabetic subjects with CKD. Only 40.4% of patients were taking statins; 31.1% and 2.8% subjects with anemia were receiving iron and erythropoiesis-stimulating agents, respectively. CONCLUSION: This study highlights the missed opportunities for improving outcomes through appropriate prescriptions of drugs in patients with CKD. There is need for dissemination of evidence-based guidelines and institution of sustainable implementation practices for improving the overall health of patients with CKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Prasad N, Yadav AK, Kundu M, et al. Prescription Practices in Patients With Mild to Moderate CKD in India. Kidney Int Rep. 2021. PMID: 34514206. doi:10.1016/j.ekir.2021.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。